Abbott Laboratoriesvs.Labcorp
ABT vs LH · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Abbott Laboratories is about 6.8× larger than Labcorp by market cap; Labcorp trades at the lower P/E (25.3 vs 31.8); year to date, Labcorp leads (+25.2% vs −21.4%).
Supply-chain link: Abbott Laboratories supplies Labcorp.
Side by side
| ABT | LH | |
|---|---|---|
| Market cap | $172B | $25.3B |
| Price | $99.60 | $312.15 |
| Today | +1.1% | −0.7% |
| Return YTD | −21.4% | +25.2% |
| Return 1Y | −26.6% | +13.2% |
| Since June 26, 2026 | +5.8% | +15.0% |
| P/E | 31.8 | 25.3 |
| P/S | 3.7 | 1.8 |
| P/B | 3.4 | 2.9 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Abbott LaboratoriesABT
In vitro diagnostics, medical devices that include the Libre glucose sensors, nutrition products and generic medicines: Abbott runs all four.
Full ABT profile →LabcorpLH
Samples from across the US end up in Labcorp's laboratories, which handle routine clinical testing alongside genomics and specialty assays. A contract research arm works for drug developers.
Full LH profile →More ABT & LH comparisons
Other head-to-heads in the Diagnostics segment.